Dr. Gershon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
ECC 256
https://sites.google.com/view/timothygershonlabemory/home
Atlanta, GA 30322Phone+1 404-785-5437- Is this information wrong?
Summary
- I am a board certified Neurologist with Special Qualification in Child Neurology. I also run a research lab that studies microcephaly and pediatric brain tumors as disorders of brain growth. To learn more, please visit:
https://sites.google.com/view/timothygershonlabemory/home
I completed fellowship training in Neuro-oncology at Memorial Sloan Kettering Cancer Center. My areas of expertise are medulloblastoma and neurofibromatosis, and the use of targeted inhibitors to treat neurologic disease.
Education & Training
- New York Presbyterian Hospital (Cornell Campus)Fellowship, Child Neurology, 2001 - 2004
- New York Presbyterian Hospital (Cornell Campus)Residency, Pediatrics, 1999 - 2001
- Columbia University Vagelos College of Physicians and SurgeonsClass of 1999
Certifications & Licensure
- GA State Medical License 2022 - 2026
- NC State Medical License 2009 - 2023
- NY State Medical License 2001 - 2011
- American Board of Psychiatry and Neurology Neurology with Special Qualification in Child Neurology
Clinical Trials
- PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1) Start of enrollment: 2013 Jan 16
- MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Start of enrollment: 2019 Sep 29
Publications & Presentations
PubMed
- Chronic AMPK inactivation slows SHH medulloblastoma progression by inhibiting mTORC1 signaling and depleting tumor stem cells.Malawsky, D., Dismuke, T., Liu, H., Castellino, E., Brenman, J., Dasgupta, B., Tikunov, A., Gershon, T.> ;Iscience. 2023 Dec 15
- 3 citationsRadiotherapy-Induced Neurocognitive Impairment Is Driven by Heightened Apoptotic Priming in Early Life and Prevented by Blocking BAX.Rumani Singh, Stacey Yu, Marwa Osman, Zintis Inde, Cameron Fraser, Abigail H Cleveland, Nicole Almanzar, Chuan Bian Lim, Gaurav N Joshi, Johan Spetz, Xingping Qin, Sne...> ;Cancer Research. 2023 Oct 13
- Preventing recurrence in Sonic Hedgehog Subgroup Medulloblastoma using the OLIG2 inhibitor CT-179.Yuchen Li, Chaemin Lim, Taylor Dismuke, Daniel S Malawsky, Sho Oasa, Zara C Bruce, Carolin Offenhäuser, Ulrich Baumgartner, Rochelle C J D'Souza, Stacey L Edwards, Jul...> ;Research Square. 2023 Jun 9
- Join now to see all
Press Mentions
- Experimental Medulloblastoma Treatment Gets a Boost with NanoparticlesFebruary 25th, 2022
- Case Reports Underscore Risk of Cerebral Edema, AFCE in Children with COVID-19October 7th, 2021
- Researchers Find Clues to Drug Resistance in Medulloblastoma SubtypeJanuary 14th, 2020
- Join now to see all
Hospital Affiliations
- Children's Healthcare of AtlantaAtlanta, Georgia
- Caldwell UNC Health CareLenoir, North Carolina
- Caldwell UNC Health CareLenoir, North Carolina
- Caldwell UNC Health CareLenoir, North Carolina
- Caldwell UNC Health CareLenoir, North Carolina
- Caldwell UNC Health CareLenoir, North Carolina
- Caldwell UNC Health CareLenoir, North Carolina
External Links
- Lab Websitehttps://sites.google.com/view/timothygershonlabemory/home
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: